Harpoon Therapeutics
South San Francisco
About Harpoon Therapeutics
Harpoon Therapeutics is a clinical-stage immunotherapy company developing a novel class of T cell engagers that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases. T cell engagers are engineered proteins that direct a patient’s own T cells to kill target cells that express specific proteins, or antigens, carried by the target cells. Using its proprietary Tri-specific T cell Activating Construct∩âö (TriTAC), platform, Harpoon is developing a pipeline of novel T cell engagers, or TriTACs, initially focused on the treatment of solid tumors and hematologic malignancies. Harpoon's first drug candidate, HPN424, is currently in Phase 1 clinical trial as a treatment for prostate cancer.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 51 – 100
- Estimated revenue: $50K – $100K
- Total funding: $255.0M
- Funding stage: M&A
- Last round: Post-IPO Equity (Oct 2023)
- Ticker: nasdaq:HARP
- Website: harpoontx.com
- Phone: 650-443-7400
Industries & Categories
Biotechnology, Health Care, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/harpoon-therapeutics-186423 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.